Back to Search
Start Over
A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment
- Source :
- International Journal of Clinical Practice
- Publication Year :
- 2017
- Publisher :
- Hindawi Limited, 2017.
-
Abstract
- SummaryAims To assess the safety and efficacy of omarigliptin in subjects with type 2 diabetes mellitus (T2DM) and chronic renal impairment (RI). Methods Patients with T2DM with moderate RI (estimated glomerular filtration rate [eGFR] ≥30 to
- Subjects :
- Male
medicine.medical_specialty
Combination therapy
Population
Renal function
030209 endocrinology & metabolism
Type 2 diabetes
Placebo
Heterocyclic Compounds, 2-Ring
Gastroenterology
Drug Administration Schedule
law.invention
03 medical and health sciences
0302 clinical medicine
Double-Blind Method
Randomized controlled trial
law
Internal medicine
Diabetes mellitus
medicine
Humans
Hypoglycemic Agents
030212 general & internal medicine
education
Aged
Pyrans
Glycated Hemoglobin
Original Paper
Dipeptidyl-Peptidase IV Inhibitors
education.field_of_study
business.industry
General Medicine
Middle Aged
medicine.disease
Original Papers
Discontinuation
Surgery
Diabetes Mellitus, Type 2
Kidney Failure, Chronic
Female
business
Glomerular Filtration Rate
Subjects
Details
- ISSN :
- 13685031
- Volume :
- 71
- Database :
- OpenAIRE
- Journal :
- International Journal of Clinical Practice
- Accession number :
- edsair.doi.dedup.....7e925478d929eeb80dd309fcc88dc073